Latest "Enhancement bone formation transduced MSCs biomimetic nano hydroxyapatite" News Stories

Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells

Bone remodeling involves a coupled balance between bone resorption and bone formation. Xu Cao and his colleagues have shown before that mesenchymal stem cells (MSCs) are recruited to the surface of the bone during this process. They now show that ins...

Nano Labs Announces New Technology to Produce Medical Hydroxyapatite

DETROIT, May 16, 2013 (GLOBE NEWSWIRE) -- Nano Labs Corp. (OTCQB:CTLE) is pleased to announce today the development of a new nanotechnology to convert eggshells into hydroxyapatite, which is a material employed for endodontics, restorative dentistry and other applications in orthopedics and prosthesis. Bone and teeth are formed of an organic component, collagen, and a mineral phase, hydroxyapat...

BioMimetic Buy Could Augment Wright's Orthopaedic Offering

By EP Vantage:Despite the chequered past of the Augment Bone Graft, Wright Medical (WMGI) has struck a deal to acquire it along with its maker, BioMimetic Therapeutics (BMTI), and BioMimetic's portfolio of foot and ankle devices in a deal worth up to $390m, or roughly three times the target company's Novembe

Wright Medical Augments Ortho Extremities Biz With BioMimetic Purchase

Firm expects to gain PMA approval in 2013 for BioMimetic’s Augment bone graft as a replacement for autologous bone graft in foot and ankle fusion procedures. Deal includes $190 million down, and up to $190 million more in milestone payments.

BioMimetic submits more data on bone graft product

(Reuters) - BioMimetic Therapeutics Inc said it submitted additional data sought by health regulators for the marketing approval of the company's bone graft product, sending its shares up 14 percent after the bell.

Wright Medical, BioMimetic to merge

Orthopedic medical device company Wright Medical Group Inc. (NASDAQ:WMGI) will merge with BioMimetic Therapeutics Inc. (NASDAQ:BMTI) in a cash and stock deal that values BioMimetic at up to $380 million comprising $190 million up front and a continge...

Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification

Analytical techniques reveal that spherical calcium phosphate particles are the first mineralized structures to be formed in the calcification process in cardiovascular tissues. Furthermore, the inner sections of calcified lesions in patients with va...

Wright Medical Technology to buy BioMimetic Therapeutics for up to $380 million

Wright Medical Group and BioMimetic Therapeutics have entered into a definitive agreement for a business combination of Wright and BioMimetic, both publicly traded, Tennessee-based companies. Wright is an orthopedics company with a market-leading lower extremities franchise. BioMimetic is focused on developing regenerative medicine products to promote the healing of musculoskeletal injuries and di...

'Novel, effective' brain cancer treatment using genetic material from bone marrow cells

In a first-of-its-kind experiment using microvesicles generated from mesenchymal bone marrow cells (MSCs) to treat cancer, neurological researchers have discovered a novel approach for treatment of tumor. Specifically, the research team found that in...

Wnt Signaling in Bone Formation and Therapeutic Potential

Learn more on the significance of Wnt signaling in bone formation -- and its potential therapeutic role in bone disorders. Therapeutic Advances in Musculoskeletal Disease

Estrogen receptor activity is dependent on bone tissue type

Bone mass is determined by the balance of two opposing activities: bone removal by osteoclasts and bone formation by osteoblasts. Additionally, there are two types of bone tissue: cancellous bone makes up the spongy interior, while cortical bone form...

[BioMimetic], [Wright Medical] merge in cash and stock deal

Public medical device firms [Wright Medical Group Inc.] (orthopedics) and [BioMimetic Therapeutics Inc.] (regenerative medicine) have agreed to merge in a deal valued at $183mm in cash and stock, plus up to another $183mm in potential earn-outs. For...

Zoledronate Boosts Sclerostin, Which Slows Bone Formation

A small study in women with osteoporosis finds that although zoledronate stops bone loss, it also acts to increase levels of sclerostin, which in turn dampens bone formation. Medscape Medical News

Novel Brain Cancer Treatment Uses Genetic Material From Bone Marrow Cells

In a first-of-its-kind experiment using microvesicles generated from mesenchymal bone marrow cells (MSCs) to treat cancer, neurological researchers at Henry Ford Hospital have discovered a novel approach for treatment of tumor. Specifically, the rese...

Bone Loss Due To Alcoholism May Be Reclaimed By Abstinence From Alcohol Plus Physical Exercise

Osteoporosis, or reduced bone mineral density (BMD), is defined by an absolute decrease in total bone mass, caused mostly by an imbalance between osteoclastic bone resorption and osteoblastic bone formation. Reduced BMD often co-occurs with alcoholis...

Researchers discover brain cancer treatment using genetic material from bone marrow cells

(Henry Ford Health System) In a first-of-its-kind experiment using microvesicles generated from mesenchymal bone marrow cells (MSCs) to treat cancer, neurological researchers at Henry Ford Hospital have discovered a novel approach for treatment of tu...

Hydroxyapatite coating on bone grafts may increase likelihood of successful implants

Coating a bone graft with an inorganic compound found in bones and teeth may significantly increase the likelihood of a successful implant, according to Penn State researchers.

Law Office of Brodsky & Smith, LLC Announces Investigation of BioMimetic Therapeutics, Inc.

BALA CYNWYD, Pa., Nov. 20, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of BioMimetic Therapeutics, Inc. ("BioMimetic" or the "Company") (Nasdaq- BMTI) relating to the proposed acquisition by Wright Medical Group, Inc. ("Wright"). Under the terms of the transaction, BioMimetic shareholders will...

BioMimetic gains on PMA amendment

BioMimetic Therapeutics Inc. (NASDAQ:BMTI) gained $0.66 (24%) to $3.46 on Tuesday after submitting to FDA an amendment to the PMA for Augment Bone Graft, which is under review for use as an alternative to autograft in hindfoot and ankle fusion proced...

New insights into how MSCs ‘traffic’ from the circulation into tissues

Mesenchymal stem cells (MSCs), are a newly emerging cellular therapy being tested in approximately 250 clinical trials worldwide to help repair damaged tissues, such as injured heart muscle following a heart attack. The problem is that when culture-e...

Using bone marrow to treat brain cancer

In a first-of-its-kind experiment using microvesicles generated from mesenchymal bone marrow cells (MSCs) to treat cancer, neurological researchers at Henry Ford Hospital have discovered a novel...

Even minor physical activity may benefit bone health in premenopausal women

A study to be published in the Endocrine Society's Journal of Clinical Endocrinology and Metabolism (JCEM) suggests that physical activity for premenopausal women is very effective in reducing sclerostin—a known inhibitor of bone formation. In a...

Bone Drug Lowers Levels of Bone Growth Markers (CME/CE)

(MedPage Today) -- A drug used to preserve bone mineral density might also have an undesirable effect that blocks bone formation, Italian investigators reported.

Physical Activity In Premenopausal Women Reduces Hormone That Inhibits Bone Formation

A study to be published in the Endocrine Society's Journal of Clinical Endocrinology and Metabolism (JCEM) suggests that physical activity for premenopausal women is very effective in reducing sclerostin - a known inhibitor of bone formation. In addi...

BioMimetic Amends Augment Bone Graft PMA, Expects Approval By 2014

BioMimetic Therapeutics submits PMA amendment for its Augment bone graft device to address questions raised by FDA in a “not approvable” letter disclosed in January.